Private Eye

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Off-market insider buying at IMV (T:IMV)

Updated Friday Jul 30, 2021 02:22 AM EDT

Fonds de solidarit? FTQ, a 10% Holder, acquired 1,428,571 Common Shares on a direct ownership basis at a price of US$1.75 through a prospectus or prospectus exempt offering on July 20th, 2021. The insider also acquired 1,071,429 Warrants with an exercise price of US$2.100 for 60 months. This represents a $3,182,499 investment into the company's shares and an account share holdings change of 27.9%.

IMV is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company's platform, DPX. The Company's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II clinical trials in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. Its T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in its platform (DPX). DPX-Survivac is designed to generate a cytotoxic T cell response against cancer cells offering survivin peptides on their surface.

INK Edge Outlook

6 months ago
1 year ago
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at
Two-week free trial for first time users.
Go to IMV Inc. (IMV)'s company page

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).

Comment On!

No Comments


Search (past week) for $IMV.CA

  • No tweets found